Akouos Inc. is a precision genetic medicine company. The Company is focused on developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss. The Company has developed a precision genetic medicine platform that incorporates a vector library consisting of variants of a small virus commonly used in gene therapy, known as adeno-associated virus (AAV) and a delivery approach. The Company is focused on executing on its strategic initiatives, which include the advancement of its lead product candidate, AK-OTOF, and expansion of its pipeline and development of internal manufacturing capabilities. In addition to this, the Company’s other programs include CLRN1 for Usher Type IIIA and GJB2 for a common form of monogenic deafness and hearing loss.